Literature DB >> 17320465

Cytokine gene transfer for cancer therapy.

Osvaldo L Podhajcer1, María Verónica Lopez, Guillermo Mazzolini.   

Abstract

The possibility of inducing a strong immune response to impair tumor growth by ectopically expressing cytokines, followed by the generation of an antitumor memory raised great hopes and enthusiasm as a therapeutic approach. However, the efficacy of this strategy on established tumor models appeared low and the initial results in the clinics were disappointing. Recently, new evidence indicates that cytokine gene combination or the combined use of cytokine genes with additional gene therapy approaches induces a synergistic effect supporting the use of cytokine gene therapy to improve the clinical outcome for cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320465     DOI: 10.1016/j.cytogfr.2007.01.014

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  12 in total

1.  In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy.

Authors:  S Denies; F Combes; C Ghekiere; S Mc Cafferty; L Cicchelero; N N Sanders
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

2.  Recent Advances in Gene Therapy for Cancer Theranostics.

Authors:  Hannah J Vaughan; Jordan J Green
Journal:  Curr Opin Biomed Eng       Date:  2021-07-15

Review 3.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

4.  Eriobotrya japonica hydrophilic extract modulates cytokines in normal tissues, in the tumor of Meth-A-fibrosarcoma bearing mice, and enhances their survival time.

Authors:  Heba A Alshaker; Nidal A Qinna; Fadi Qadan; Mona Bustami; Khalid Z Matalka
Journal:  BMC Complement Altern Med       Date:  2011-02-04       Impact factor: 3.659

5.  Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.

Authors:  Song-Nan Zhang; Il-Kyu Choi; Jing-Hua Huang; Ji-Young Yoo; Kyung-Ju Choi; Chae-Ok Yun
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

6.  Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.

Authors:  Irina V Alekseenko; Eugene V Snezhkov; Igor P Chernov; Victor V Pleshkan; Victor K Potapov; Alexander V Sass; Galina S Monastyrskaya; Eugene P Kopantzev; Tatyana V Vinogradova; Yuri V Khramtsov; Alexey V Ulasov; Andrey A Rosenkranz; Alexander S Sobolev; Olga A Bezborodova; Anna D Plyutinskaya; Elena R Nemtsova; Raisa I Yakubovskaya; Eugene D Sverdlov
Journal:  J Transl Med       Date:  2015-03-04       Impact factor: 5.531

Review 7.  shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy.

Authors:  Jie Zhang; Meng Ding; Kai Xu; Lijun Mao; Junian Zheng
Journal:  Oncotarget       Date:  2016-05-17

8.  Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

Authors:  Jing-Hua Huang; Song-Nan Zhang; Kyung-Ju Choi; Il-Kyu Choi; Joo-Hang Kim; Min-Geol Lee; Mingul Lee; Hoguen Kim; Chae-Ok Yun
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

9.  Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.

Authors:  Il-Kyu Choi; Yan Li; Eonju Oh; Jaesung Kim; Chae-Ok Yun
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

10.  Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.

Authors:  Hyo Min Ahn; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2016-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.